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Aims This prospective, multicentre study (PRECISION GOLD) evaluated the incidence of asymptomatic cerebral embolism
(ACE) after pulmonary vein isolation (PVI) using a new gold multi-electrode radiofrequency (RF) ablation catheter,
pulmonary vein ablation catheter (PVAC) GOLD. Also, procedural efficiency of PVAC GOLD was compared with
ERACE. The ERACE study demonstrated that a low incidence of ACE can be achieved with a platinum multi-electrode
RF catheter (PVAC) combined with procedural manoeuvres to reduce emboli.
Methods
and results
A total of 51 patients with paroxysmal atrial fibrillation (AF) (age 57+ 9 years, CHA2DS2-VASc score 1.4+1.4) under-
went AF ablation with PVAC GOLD. Continuous oral anticoagulation using vitamin K antagonists, submerged catheter
introduction, and heparinization (ACT ≥ 350 s prior to ablation) were applied. Cerebral magnetic resonance imaging
(MRI) scans were performed within 48 h before and 16–72 h post-ablation. Cognitive function assessed by the Mini-
Mental State Exam at baseline and 30 days post-ablation. New post-procedural ACE occurred in only 1 of 48 patients
(2.1%) and was not detectable on MRI after 30 days. The average number of RF applications per patient to achieve PVI
was lower in PRECISION GOLD (20.3+ 10.0) than in ERACE (28.8+ 16.1; P ¼ 0.001). Further, PVAC GOLD abla-
tions resulted in significantly fewer low-power (,3 W) ablations (15 vs. 23%, 5 vs. 10% and 2 vs. 7% in 4:1, 2:1, and 1:1
bipolar:unipolar energy modes, respectively). Mini-Mental State Exam was unchanged in all patients.
Conclusion Atrial fibrillation ablation with PVAC GOLD in combination with established embolic lowering manoeuvres results
in a low incidence of ACE. Pulmonary vein ablation catheter GOLD demonstrates improved biophysical efficiency
compared with platinum PVAC.
Trial registrationClinicalTrials.gov NCT01767558.
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Introduction
Pulmonary vein isolation (PVI) is an effective therapy for paroxysmal
atrial fibrillation (AF). The pulmonary vein ablation catheter (PVAC)
has shown promising clinical results in single-centre studies.1 – 4 In
recent years, several reports have identified the occurrence of
new asymptomatic cerebral embolism (ACE) on cerebral magnetic
resonance imaging (MRI) following AF ablation with an overall inci-
dence of 1.7–40%, depending on the ablation technology used.5–11
Gaita et al. and Siklo´dy et al. reported a significantly higher ACE
incidence after PVI with the PVAC, when compared with irrigated
focal radiofrequency (RF) and cryoballoon ablation.8,9
The prospective, multicentre ERACE study, however, demon-
strated a significantly reduced ACE incidence (1.7%) with the imple-
mentation of procedural modifications, which included: (1) avoiding
proximity of energized electrodes, (2) uninterrupted oral anticoagu-
lation (OAC) and targeted procedural activated clotting time (ACT)
≥350 s, and (3) submerged catheter introduction.6
The next-generation multi-electrode catheter, PVAC GOLD, was
designed to mitigate embolus formation and improve the delivery of
RF energy compared with the platinum PVAC.12 The purpose of the
Phased RF Evaluation of a Cute Pulmonary Vein ISolation In ParOx-
ysmal AF with New GENius UI and PVACw GOLD (PRECISION
GOLD) study was to evaluate the ACE incidence after AF ablation
using the new PVAC GOLD. Further, procedural efficiency of PVAC
GOLD vs. platinum PVAC was compared based on biophysical data
obtained in the ERACE study.
Methods
Patient population
The study population consisted of paroxysmal AF patients enrolled at
10 centres experienced with the PVAC and GENius generator (Phased
RF system, Medtronic Ablation Frontiers, Carlsbad, CA, USA). Patients
with symptomatic AF between 18 and 70 years of age who had previously
failed at least one anti-arrhythmic drug (AAD) were included. Exclusion
criteria were prior AF ablation, persistent or permanent AF, invasive
cardiac procedure in preceding 90 days, history of stroke or transient
ischaemic attack (TIA) within 6 months, contraindication to MRI,
contraindication to vitamin K antagonists (VKA), or active thrombus
in the left atrium (LA). Patients with heart failure were included based
on medical history and were categorized using the New York Heart As-
sociation (NYHA) Class I, II, III, or IV. The study was approved by each
centre’s ethics review board, and all patients provided written informed
consent prior to study inclusion. The study was registered on Clinical-
Trials.gov NCT01767558.
A total of 56 patients were enrolled, and 51 patients underwent ab-
lation for the primary analysis cohort (Figure 1). Five patients exited
prior to ablation due to sub-therapeutic international normalized ratio
(INR) (n ¼ 3), or inclusion/exclusion criteria not met (n ¼ 2). Forty
eight of the 51 patients were included in the ACE analysis, after refusing
post-procedure MRI (n ¼ 2) and undergoing an ablation in the LA with a
non-study device (n ¼ 1). See the supplementary material online for
subject disposition details.
Study design
The study was a prospective, multicentre study to evaluate ACE findings
in patients with symptomatic paroxysmal AF undergoing ablation with
PVAC GOLD. Patients underwent protocol-specific evaluations at the
pre-procedure, discharge, and 1-month visits. Cerebral MRIs were per-
formed at pre- and post-procedure visits (see Cerebral MRI Imaging and
Neurological Assessments section). Additionally, cognitive function was
assessed by the Mini-Mental State Exam (MMSE) at pre-procedure and
1-month visits. The PRECISION GOLD study was designed similarly to
the ERACE study, employing the same embolic lowering procedural
manoeuvres.
Peri-procedural anticoagulation
Oral anticoagulation with VKA was initiated at least 3 weeks prior to ab-
lation to achieve an INR of ≥2.0 on the day of ablation and continued for
the duration of the study. To rule out LA thrombus, transoesophageal
echocardiography (TEE) was performed 48 h before ablation. Heparin
was administered prior to and/or immediately after transseptal puncture
What’s new?
† This is the first multicentre, prospective clinical study with
the new pulmonary vein ablation catheter (PVAC) GOLD ab-
lation catheter.
† New PVAC GOLD design avoids key source of micro-emboli
(interaction of electrodes 1 and 10).
† Study shows a low (2.1%) incidence of ACE with PVAC
GOLD catheter, which is among the lowest reported for
any ablation technology.
† High prevalence of pre-existing cerebral lesions (73%) in pa-
tients with paroxysmal AF, which may have an important im-
plication for maintaining sinus rhythm and therapeutic
anticoagulation.
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Figure 1 Enrolled patient disposition of primary analysis cohort.
Disposition of enrolled patients, including screen failures.
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and sustained throughout the procedure to maintain ACT levels
≥350 s, with monitoring at least every 30 min.
Ablation protocol and procedural techniques
After a single transseptal puncture, a 10Fr or larger sheath was inserted
into the LA. Submerged loading of PVAC GOLD into the introducer, as
well as continuous flushing of the sheath with heparinized saline, was
performed to minimize air ingress. Pulmonary vein ablation catheter
GOLD was advanced slowly through the sheath into the LA. Pulmonary
veins (PVs) were electrically isolated by targeted ablation of each PV-LA
antrum. Pulmonary vein isolation was defined as PV-LA entrance
block verified with pacing manoeuvres, as appropriate. Sinus rhythm
(SR) was restored by cardioversion at the end of the procedure
as needed.
Pulmonary vein ablation catheter technology has been described
previously.1,13 Briefly, the GENius generator delivers duty-cycled
bipolar and unipolar phased RF energy to all or selected electrode
pairs. Radiofrequency is delivered in a temperature-controlled and
power-limited fashion (608C, maximum 10 W) with typical ablation
duration of 60 s.
Pulmonary vein ablation catheter GOLD features several modifica-
tions to mitigate embolus formation and to improve the efficiency of
RF delivery, compared with the predicate platinum electrode PVAC.
First, the 10th/proximal electrode was removed to eliminate the poten-
tial to produce emboli that can occur when electrodes 1 and 10 are en-
ergized in close proximity.14 To maintain the effective arc length,
inter-electrode spacing was increased from 3.00 to 3.75 mm. Next,
gold electrodes were utilized, due to higher thermal conductivity and
potential for reducing coagulum formation and increasing power output
vs. platinum electrodes.12,15 Finally, a 208 forward tilt was applied for a
more uniform contact across the electrode array (Figure 2).
Biophysical parameters analysis
The total number of RF applications and the proportion of energy deliv-
eries with low power (,3 W) were calculated. Further, the efficiency of
energy transfer was evaluated by measuring effective contact (EC), de-
fined as the number of seconds when an electrode had temperature
≥508C and power ≥3 W, and effective energy (EE), defined as the total
number of Joules delivered for each electrode during EC. The biophysics
parameters from the PRECISION GOLD were compared with those
collected during the ERACE study.
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Figure 2 Pulmonary vein ablation catheter GOLD (A) and
PVAC (B). Main design changes of PVAC GOLD are 9 (removed
electrode 10) gold electrodes, increased inter-electrode spacing
to 3.75 mm, and the 208 tilt. See text for further explanation.
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Table 1 Baseline demographics of primary analysis cohort and patients with and without PELs
Baseline variable Primary analysis cohort
(N 5 51)
No PEL (N 5 14) PEL (N 5 37) P-value
Age (years) 57.1+8.8 52.4+7.8 58.8+8.6 0.0171
Gender, male (%) 40 (78.4%) 13 (93%) 27 (73%) 0.2508
History of AF in years 3.9+3.7 2.6+2.3 4.4+4.1 0.0517
Number of patients with ≥10 AF episodes in 3 months
prior to enrolment (%)
16 (31.4%) 8 (57%) 8 (22%) 0.0396
Patients with DC cardioversion for AF in past 12 months (%) 9 (17.6%) 2 (14%) 7 (19%) 1.0000
Patients with hospital admission for AF in past 12 months (%) 19 (37.3%) 3 (21%) 16 (43%) 0.2023
CHA2DS2-VASc 1.4+1.4 0.5+0.7 1.8+1.5 0.0001
Hypertension (%) 16 (31.4%) 3 (20%) 13 (35%) 0.5030
Heart failure (%) 15 (29.4%) 2 (14%) 13 (35%) 0.1843
Dyslipidemia (%) 16 (31.4%) 4 (29%) 12 (32%) 1.0000
Diabetes (%) 1 (2.0%) 0 (0%) 1 (3%) 1.0000
Atrial tachycardia (%) 2 (3.9%) 1 (7%) 1 (3%) 0.4776
Atrial flutter (%) 3 (5.9%) 1 (7%) 2 (5%) 1.0000
Coronary artery disease (%) 5 (9.8%) 1 (7%) 4 (11%) 1.0000
Data are presented as mean+ SD or number (%) of patients.
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Cerebral magnetic resonance imaging
and neurological assessments
Cerebral magnetic resonance imagings (MRIs) were performed using a
1.5 T scanner as previously described.5,6 Scans were performed within
48 h pre- and 24 h post-ablation (window 16–72 h) in all patients. In
case of a new ACE finding, MRI was repeated after 1 month. The number
and size of all ACE findings were recorded. All MRIs were interpreted by a
Core Lab, with two independent, blinded, neuro-radiologist reviewers. In
cases of disagreement, reviewers reached a consensus prior to final adju-
dication. The ACE definition used in this trial was identical to that previ-
ously described by Verma et al. and Gaita et al.5,6 Briefly, post-procedural
ACE findings were defined as any new focal hyperintensities detected on
the post-ablation fluid-attenuated inversion recovery (FLAIR) sequences,
corresponding to restricted diffusion on the diffusion-weighted (DW) se-
quences and not ruled out by shine-through artefact on apparent diffusion
coefficient (ADC) maps. Pre-ablation abnormalities on cerebral MRI
were categorized as an acute pre-existing lesion (PEL) if hyperintensities
were detected on the DW sequence, while a chronic PEL if detected only
on the FLAIR sequence. The number and size of PELs were recorded. All
patients underwent cognitive assessment at the pre-procedure and
1-month visits with the MMSE-2 (PAR, Lutz FL).
Study endpoints
The primary study endpoint was the incidence of new ACE findings on
post-procedure cerebral MRI. Secondary endpoints included acute pro-
cedural success (APS)—defined as ability to achieve PVI with only PVAC
GOLD and restoration of SR with or without cardioversion—as well as
all serious adverse events (SAEs) that were related to the procedure
and/or ablation system. All SAEs were adjudicated by a Clinical Events
Committee. Ancillary objectives included total procedure time, LA
dwell time, fluoroscopy time, total energy delivery, number of RF appli-
cations per vein, energy modes used, and results of MMSE.
Statistical analysis
Clinically relevant variables are summarized using descriptive statistics,
including mean+ standard deviation for continuous variables and per-
centages and counts for categorical variables. Comparisons were per-
formed using Pearson’s x2 test for categorical variables and Student’s
t-test for continuous variables. Binomial confidence intervals (95% CI)
were calculated using the Clopper–Pearson method. An analysis of co-
variance model was used to compare changes in MMSE scores from
baseline to 1 month, adjusting for baseline score. The relationship be-
tween PELs and baseline variables was modelled using ordinal logistic
40% 38%
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<5 ≥10
32%35%
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Figure 3 Pre-existing lesion burden in study population. One patient had two acute PELs detected (arrows) visible on both pre- and post-
ablation DW (A and B) and FLAIR sequences (C and D), as well as .10 chronic PELs (not shown). Most patients (73%) had chronic PELs detected
on FLAIR (E). The lower portion of E shows the distribution of PELS/patient.
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regression. Effective contact of ≥30 s was analysed using logistic regres-
sion with generalized estimating equation (GEE) methodology to
account for potential correlation between the EC of different electro-
des during the same RF ablation. A compound symmetry working cor-
relation was used, and the likelihood of EC was adjusted for the duration
each electrode was turned on and energy mode. A similar GEE linear
regression was used to analyse EE delivery. A P-value of ,0.05 was con-
sidered statistically significant. Statistical analyses were conducted with
SAS 9.2 (Cary, NC).
Results
Patient characteristics
From December 2013 to July 2014, 51 patients were enrolled
and treated in the study with baseline characteristics detailed in
Table 1.
Pre-existing cerebral magnetic resonance
imaging lesions
Chronic PELs were identified in 37 of the 51 (73%) patients with 33
(62%) patients having .5 PELs (Figure 3, right panel). These were
localized in the frontal (59%), parietal (31%), occipital (6%), and
temporal lobes (5%). Patients with chronic MRI findings were older
(P ¼ 0.0171), had higher CHA2DS2-VASc (P ¼ 0.0001), but had
less episodes of AF (P ¼ 0.0396) in the 3 months prior to ablation
(Table 1). Using logistic regression, there was a significant relation-
ship between chronic PELs and CHA2DS2-VASc score, with each
point of CHA2DS2-VASc score associated with an odds ratio of
2.00 (95% CI 1.31–3.06, P ¼ 0.001) for a higher level of chronic
PELs/patient. In addition to chronic PELs detected on FLAIR, acute
PELs were identified on DW for one patient. In this patient,
pre-ablation images showed two acute PELs on DW (Figure 3, left
cerebellum) as well as .10 chronic PELs on FLAIR. Patients with
PELs did not demonstrate cognitive differences with a mean
pre-ablation MMSE score of 29.0+1.0 compared with 28.7+ 1.5
in patients without PELs (P ¼ 0.53).
Procedural parameters
The mean INR was 2.7+ 0.6 on the day of the procedure, with an
average ACT of 462+ 166 s (Table 2). The majority of patients
(78%) were in SR at the start of the procedure. Twenty-nine
(57%) patients had rhythm conversions during the course of the ab-
lation (45% spontaneous, 20% electrical, and 14% pharmacological).
Pulmonary vein ablation catheter GOLD was able to electrically iso-
late 97% (197/204) of the targeted PVs, and 94% (48/51) of patients
had all accessible PVs isolated, including one patient in which con-
ventional RF was used to complete isolation of one PV and two
patients in which one PV was not isolated. In addition, two other pa-
tients failed cardioversions despite achieving PVI, resulting in 90%
(46/51) APS. The mean total procedure time was 104+ 31 min
with a LA dwell time of 59+ 18 min and a fluoroscopy time of
16+7 min (Table 2). At the 1-month follow-up visit, 44/51 patients
(86%) were in SR.
Procedural and biophysical parameters
The PRECISION GOLD procedural and biophysical data were com-
pared with the data from the ERACE study. There were no signifi-
cant differences in procedural time, LA dwell time, or energy modes
between the studies (Table 2). However, mean INR levels before
and mean ACT and the average of the minimum ACT/patient during
ablation were higher in PRECISION GOLD.
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Table 2 Procedure and biophysical parameters of primary analysis cohort, in comparison with ERACE
Procedure parameters PRECISION GOLD (N 5 51) ERACE (N 5 60) P-value
Mean INR 2.7+0.6 2.4+0.5 0.0056
Patients with INR ≥ 2.0 94.1% (48) 88.3% (53) 0.2888
Mean ACT (s) 462.3+166.1 405+116 0.0413
Patients with ≥2 consecutive ACTs ,300 0.0% (0) N/A N/A
Patients with ≥2 consecutive ACTs ,350 9.8% (5) N/A N/A
ACT—per-patient minimum (s) 414.5+149.4 319+130 0.0006
Procedure time (min) 103.9+31.4 100+35 0.5375
LA dwell time (min) 59.5+18.3 64+27 0.3007
Fluoroscopy time (min) 15.6+6.9 N/A N/A
Biophysical parameters
Total RF applications 20.3+10.0 28.8+16.1 0.0010
LSPV RF applications 6.0+4.5 8.2+5.9 0.0293
LIPV RF applications 5.0+3.8 6.2+4.1 0.1379
RSPV RF applications 4.8+2.2 7.2+4.8 0.0006
RIPV RF applications 4.4+2.9 6.2+4.5 0.0132
Energy mode 1:1 (per-patient %) 6.6+18.4 6.7+16.3 0.9584
Energy mode 2:1 (per-patient %) 56.6+40.3 67.0+38.0 0.1707
Energy mode 4:1 (per-patient %) 36.8+42.1 26.5+39.6 0.1904
Data are presented as mean+ SD or % (n) of patients.
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The average number of RF applications per patient in PRECISION
GOLD (20.3+ 10.0) was lower than in ERACE (28.8+ 16.1; P ¼
0.001), with significantly less RF applications needed to achieve
PVI for the left superior, right superior, and right inferior PVs
(Table 2). Pulmonary vein ablation catheter GOLD was also asso-
ciated with a significant EC increase in 2:1 mode, while all modes
showed increased EE and decreased low-power (,3 W) ablations
(Figure 4).
Incidence of ACE and neurological
findings post-ablation
Three ablated patients from the primary analysis cohort were ex-
cluded from ACE analysis for refusing post-ablation MRI (n ¼ 2)
or undergoing treatment with a non-study device (n ¼ 1).
Evaluation of post-ablation MRIs demonstrated one patient with
one new ACE finding (2.1%, 1/48, 95% CI ¼ 0.1–11.1%), located
in the left cerebellum (4 × 5 mm). This ACE finding was no longer
detectable on the 1-month MRI (Figure 5). For all patients, there was
no significant change in MMSE from baseline to the 1-month visit
with the mean difference of 0.31 (95% CI 20.02 to 0.63; P ¼ 0.06).
Serious adverse events
One patient developed pericarditis, and one patient had a groin
pseudo-aneurysm. Both events resolved without medical interven-
tion. No other SAEs were noted.
Discussion
Main findings
Main observations of the study are (1) ACE incidence after PVI using
the PVAC GOLD in combination with embolic lowering procedural
manoeuvres is 2.1%; (2) paroxysmal AF patients exhibit a high
burden of cerebral PELs, despite a low estimated stroke risk; and
(3) PVAC GOLD demonstrates improved biophysical efficiency
compared with platinum PVAC, with a low complication rate.
ACE incidence and PVAC ablation
As illustrated in Figure 6, ACE detected by DW MRI following AF ab-
lation has been reported at widely varying rates between 1.7 and al-
most 40%. Initial studies by Gaita et al. and Siklo´dy et al. raised a
safety concern for PVAC with a significantly higher rate of ACE find-
ings after PVAC ablation (38.9 and 37.5%, respectively) vs. irrigated
RF ablation (8.3 and 7.4%, respectively) and cryoballoon (5.6 and
4.3%, respectively) (Figure 6).8,9
Preclinical research to identify potential causes of ACE has
demonstrated that the most significant source of micro-emboli
(gas or particle) for PVAC occurs during an electrode-1-and-10
interaction (E1–E10), which can occur when electrodes are ener-
gized in close proximity. This creates a bipolar short circuit, resulting
in excessive tissue and blood heating. Furthermore, air ingress dur-
ing introduction into the transseptal sheath was a source of gaseous
emboli.14 Wieczorek et al. showed a significantly lower ACE inci-
dence in patients without vs. with an E1–E10 interaction (11 vs.
44%).7 Subsequently, the multicentre ERACE study showed that
submerged capture to avoid air entrapment, plus de-activation of
E1 or E10, could reduce ACE incidence to 1.7%, which is one of
the lowest rates ever published.6
Importantly, uninterrupted OAC with warfarin coupled with an
elevated procedural heparinization (target ACT .350 s) likely con-
tributed to the marked ACE reduction in this study. Recent evi-
dence has shown the importance of maintaining therapeutic
peri-procedural OAC to mitigate thromboemboli.16 – 18 Di Biase
et al. demonstrated in the randomized COMPARE study that
OAC maintenance vs. bridging with low-molecular-weight heparin
can significantly reduce peri-procedural cerebral events, 0.25 vs.
5%, respectively.16 In a similar study using irrigated tip catheters,
the ACE incidence was 2.1% for patients maintaining OAC vs.
14.2% for those who received heparin bridging.17 Additionally,
maintaining high ACT levels during ablation may further lower em-
bolic risk.19 Scaglione et al. found that higher mean intraprocedural
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Figure 4 Comparison of EC, EE, and proportion of low-power
ablations between PVAC and PVAC GOLD. The percentage of ab-
lations with .30 s of EC time (for the 2:1 mode) and EE (for all
modes) was higher during PVAC GOLD ablations (A and B).
Also, the number of low-power ablations was reduced (C).
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ACT values are protective, with no ACE occurring when mean ACT
value was .320 s.19
The primary change to PVAC GOLD for mitigating emboli forma-
tion is the removal of the 10th/proximal electrode, thereby com-
pletely eliminating the potential for E1–10 interaction. Combined
with the same embolic lowering manoeuvres as in ERACE, the
current study shows a similarly low ACE rate of 2.1%.
Pre-existing lesions: sources and impact
Several studies have shown a high prevalence of chronic PELs in AF
patients prior to ablation, ranging from 12.3 to 92%.20,21 In the cur-
rent study, a high chronic PEL prevalence (73%) and burden (≥5
PEL in 62% of patients) was observed, despite a low thromboembol-
ism risk (CHA2DS2-VASc score 1.4+1.4). This finding is also con-
sistent with the ERACE study, which found PELs in 60% of a similar
patient cohort.
In the present study, one patient had two acute PELs in the left
cerebellum, 5 × 5 and 9 × 6 mm. For studies with silent embolism
endpoints, this finding illustrates the importance of pre-ablation
imaging, as its absence would have doubled the observed post-
ablation ACE incidence in the present study. As 1-month MRI was
not performed for this patient, it is not known whether these acute
PELs would have disappeared similarly to the majority of post-
ablation ACE findings ≤10 mm in size which are not visible during
follow-up imaging.7,21 The longer-term course of spontaneous
acute PELs vs. chronic PELs, and their clinical significance, requires
further longer-term evaluation.
Although the aetiology of chronic PELs is currently unknown,
several factors may contribute including a history of AF, diabetes,
sub-therapeutic anticoagulation, hypertension, and microvascular
disease. A recent meta-analysis demonstrated that AF is associated
with a great that two-fold increase in the odds for PEL.22 Of note, in
the present study, older age and a higher CHA2DS2-VASc score
were the main predictors of PELs and not the number of AF epi-
sodes in the last 3 months before ablation. Though not seen in
this study, other reports have found a correlation between the
prevalence of PELs and increased risk of stroke, dementia, and/or
cognitive decline.23
Pre-ablation
A AA B
A
P
A
P
P P
D E
Post-ablation
AC
A
P
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F
1-month FUP
Figure 5 Pre-, post-ablation, and 1-month follow-up cerebral MRIs from single patient with ACE (S-I view). The top panels (A–C ) are DW
images, and the bottom panels (D–F ) are FLAIR images. The right column (A and D) shows pre-ablation DW and FLAIR MRI sequences showing
no PEL in the region of the ACE finding (circled). The ACE finding (circle) is identified on the immediate post-ablation MRI as a restricted diffusion
hyperintensity on both DW and FLAIR MRI sequences denoted by an arrow (B and E). Panels C and F show that at 1 month, the ACE finding is no
longer detected on DW or FLAIR MRI sequences (circle).
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Post-ablation ACE findings differ from chronic PELs in their tran-
sient nature with a low rate of chronic persistence (.30 days).6,21
In the current study, the only new ACE finding detected post-
ablation was no longer detectable after 1 month. This transient na-
ture suggests that gaseous or sub-mm particle emboli may be the
primary contributors to post-ablation ACE causing a temporary
interruption of blood flow, but not resulting in a permanent de-
tectable scar. The potential impact of transient ACE on cerebral
function might therefore be less significant, when compared with
permanent chronic PELs. As such, performing ablations earlier in
the course of AF may confer clinical benefits through a decrease
in AF burden, stroke risk, PEL incidence, and cognitive decline. Lar-
ger clinical studies with longer-term follow-up are needed to con-
firm this hypothesis.
Comparison of procedural efficiency and
safety between PVAC GOLD and PVAC
Compared with PVAC in the ERACE study, no differences were ob-
served in procedure time, LA dwell times, or mix of energy modes.
Importantly, PVAC GOLD was associated with a similarly low rate
of complications and comparable rate of PVI (94 vs. 100% in
ERACE). In contrast, less RF applications per patient and per PV (ex-
cept for the left inferior PV) were needed to achieve isolation in
PRECISION GOLD. Contributing factors likely include the in-
creased heat transfer of gold electrode material, as reflected by a
significant increase in EC and EE and a 50% reduction in low-power
ablations, and the 208 forward tilt, which provides more uniform
contact with the PV antrum. Overall, this may reflect improved
lesion formation with PVAC GOLD as Haines et al. recently demon-
strated that gold electrodes allow more efficient cooling and deeper
lesions with phased RF ablations than platinum.12 De Greef et al.
demonstrated that increased rates of low-power ablations
(,3 W) with PVAC were associated with acute PV reconnection
and clinical AF recurrence.24 In a temperature-controlled
RF ablation, low-power ablations can be caused by inadequate
circulatory cooling at the electrode–tissue interface, limiting the le-
sion depth. Kardos et al. showed that cavotricuspid isthmus ablation
was faster and required fewer RF applications using 8 mm gold vs.
platinum electrodes.25 Whether better RF biophysics results
in improved clinical outcome with PVAC GOLD remains to be
proved.
Study limitations
The present study includes a moderate number of patients without
a control group. The observed ACE incidence in this study cannot
be extrapolated to different peri-procedural anticoagulation
strategies or newer agents, as well as, persistent or longstanding per-
sistent AF patients. There are limitations to comparing the proced-
ural and biophysical data from the PRECISION GOLD and ERACE
studies, including the impact of different investigators and different
software versions for the GENius generator. Lastly, subtle changes
in cognitive function may not be detected by the MMSE.
Conclusions
The PRECISION GOLD study builds upon the preclinical work by
Haines et al., and the ERACE study providing evidence that AF abla-
tions performed with the new-generation PVAC GOLD result in
some of the lowest reported ACE rates (2.1%) for any technology.
This study shows that despite a low thromboembolic risk score and
inclusion of only paroxysmal AF patients, 73% of patients had pre-
existing cerebral lesions. Finally, the current study demonstrates
that the new PVAC GOLD with associated design changes
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demonstrate improved biophysics with similar acute safety, efficacy,
and incidence of ACE as the predicate PVAC.
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